NASDAQ · FEMY
Healthcare · Medical - Instruments & Supplies
$2.20
Up+$0.04 (+1.85%)
Updated Aug 19, 2026, 11:28 AM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
FEMY closed at $2.20 after 21 trading sessions, down 43.73% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $2.16 | $2.2489 | $2.0644 | $2.20 | 146.96K |
| Aug 17, 2026 | $2.28 | $2.2898 | $2.0223 | $2.16 | 246.25K |
| Aug 14, 2026 | $2.33 | $2.3799 | $2.26 | $2.29 | 117.25K |
| Aug 13, 2026 | $2.37 | $2.4499 | $2.2201 | $2.29 | 154.88K |
| Aug 12, 2026 | $2.60 | $2.60 | $2.19 | $2.35 | 701.26K |
| Aug 11, 2026 | $2.39 | $2.48 | $2.31 | $2.35 | 240.35K |
| Aug 10, 2026 | $2.69 | $2.8728 | $2.35 | $2.37 | 400.4K |
| Aug 7, 2026 | $3.11 | $3.1381 | $2.2908 | $2.66 | 1.09M |
| Aug 6, 2026 | $3.015 | $3.04 | $2.91 | $2.95 | 20.56K |
| Aug 5, 2026 | $3.05 | $3.14 | $2.90 | $3.01 | 30.41K |
| Aug 4, 2026 | $2.9337 | $3.21 | $2.92 | $3.05 | 48.72K |
| Aug 3, 2026 | $2.90 | $3.00 | $2.80 | $2.97 | 19.92K |
| Jul 31, 2026 | $2.91 | $3.02 | $2.8102 | $2.86 | 10.82K |
| Jul 30, 2026 | $2.83 | $2.93 | $2.83 | $2.91 | 17.91K |
| Jul 29, 2026 | $2.92 | $3.04 | $2.64 | $2.78 | 28.19K |
| Jul 28, 2026 | $3.08 | $3.08 | $2.73 | $2.92 | 82.39K |
| Jul 27, 2026 | $3.60 | $3.71 | $2.96 | $3.06 | 109.29K |
| Jul 24, 2026 | $3.80 | $3.92 | $3.59 | $3.71 | 35.27K |
| Jul 23, 2026 | $3.45 | $3.9599 | $3.39 | $3.79 | 20.96K |
| Jul 22, 2026 | $3.79 | $3.9957 | $3.49 | $3.52 | 123.46K |
| Jul 21, 2026 | $3.20 | $4.22 | $3.12 | $3.91 | 226.22K |
The latest Smart Investors Daily articles mentioning FEMY.
FEMY research
Company profile and research snapshot.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 18, 2026 | Lake Street | Buy | — |
| Aug 14, 2026 | Maxim Group | Buy | — |
| Mar 3, 2026 | Lake Street | Buy | — |
| Nov 20, 2025 | Laidlaw & Co. | Buy | — |
| Aug 11, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 7, 2026
Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce
Benzinga · Jun 4, 2026
SEC.
Benzinga · May 5, 2026
The procedure was supported by FemSperm®, enabling in-office sperm preparation and advancing the shift of fertility care to women's primary physician, where earlier intervention can improve access and
Finnhub · May 5, 2026
Integrated sperm preparation and intratubal insemination drive earlier intervention and streamlined, in-office care within routine OB/GYN practice -- ATLANTA, May 05, 2026 -- Femasys Inc. , a...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning FEMY.
